SlideShare a Scribd company logo
Prevention Strategies
for Oral Cancer
Aiman A. Ali, DDS, PhD.
Associate professor Oral Pathology
and Medicine
How to prevent the occurrence of a disease?

A disease with simple etiology
 Causal factor
 Dental caries
Traumatic exposure
Chemical irritations
Thermal irritations
Fracture of the crown

Disease
Pulpitis

Multifactorial disease (dental caries or oral cancer)?
How to prevent the occurrence of a disease?

Etiology of oral cancer
 Smoking
If we want to prevent
 Chronic irritations
the occurrence of
 Chronic diseases
oral cancer we have
 Alcohol
to control all these
factors !!!
 Hereditary
Is it possible?
 Genetic aberrations
 Others such as viruses, diet…etc.
General statistics
 Thirty

percent of all cancer deaths are caused
by tobacco.
 Over 80% of lung cancer deaths are caused
by tobacco.
 The lung cancer death rate for men was 4.9
per 100,000 in 1930 and it has increased to
75.6 per 100,000 in the decade of 1990.
 Ninety-two percent of oral squamous cell
carcinoma are attributable to tobacco usage.
Statistics and incidence

The incidence of lung cancer is highly correlated with smoking.
Statistics and incidence
The tobacco plant
was first brought to
Europe in 1558 by
the Spanish
physician Francisco
Fernandes

Aiman A. Ali, DDS, PhD. 2008
Tobacco and related oral habits
 Smoking






Cigarette (normal, black, light, natural….)
Pipe
Water-pipe
Reverse smoking
Cigar

 Smokeless



 Passive

Snuff, Tombak and similar products
Chewing the tobacco leaves

smoking
Aiman A. Ali, DDS, PhD. 2009
Tobacco and related oral habits
 Smoking


Cigarette (normal, black, light, natural….)
Tobacco and related oral habits

 Smoking


Pipe
Tobacco and related oral habits
 Smoking


Water-pipe
Tobacco and related oral habits
 Smoking


Reverse smoking
Tobacco and related oral habits
 Smoking


Cigar
Tobacco and related oral habits
 Smokeless


Snuff, Tombak and similar products
Tobacco and related oral habits
 Smokeless


Chewing the tobacco leaves
Tobacco and related oral
habits
 Passive

smoking
Smoking any tobacco product,
*%, Males
* WHO Report on the Global Tobacco Epidemic, 2008
Smoking any tobacco product, %,
Females
* WHO Report on the Global Tobacco Epidemic, 2008
Constituents


"Chemical analysis shows the tobacco leaf/smoke to contain an
unusual number of constituents.

Nicotine,
Nitric,
phosphoric,
pictic,

nicotianine,
hydrochloric,
citric, acetic,
ulmic acids

tobacco acid or malic acid
sulphuric,
oxalic,

Acetaldehyde, acrolein, ammonia, carbon monoxide,
formaldehyde, hydrogen cyanide, hydrogen sulfide,
methyl chloride, nitrogen dioxide
And others: Benzopyrene, Tar, Naphthalene, arsenic and others
Hinds JID, The Use of Tobacco (Nashville, Tenn: Cumberland Presbyterian Publishing House, 1882), p 36
Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service, PHS Pub 1103, Chapter 6, Table 4, p 60 (1964)
Constituents

Chemical structure of the
carcinogen benzopyrene diol
epoxide

Benzopyrene, a major mutagen in tobacco
smoke, in an adduct to DNA*
* PDB 1JDG
Constituents


"Moreover, there is no question that arsenic . . . is definitely an
active carcinogen on human tissue. . . .



the arsenic content of American cigarettes has increased from two
to six times in a period of 25 years.



One popular American brand contains from 41 to 52.5 micrograms
of arsenic, of which one third remains in the butt, one third is in
the ash, and one third goes into the smoke.



About five micrograms of arsenic trioxide is inhaled from each
cigarette.
Alton Ochsner, Smoking and Your Life (New York: Julian Messner Pub, 1954 rev 1964), p 15.

A large sample of native arsenic.

Aiman A. Ali, DDS, PhD. 2008
Constituents


Cigarettes and other forms of tobacco are extremely addicting and
nicotine is the drug that causes that addiction



Pharmacologic and behavioral characteristics of nicotine
addiction are similar to those of heroin, cocaine, and
methamphetamine

Nicotine molecule
Nicotine


Absorbed by the lungs via inhalational route



Absorbed topically through skin and mucous lining of the
mouth



Rapidly distributed after inhalation and reaches the brain in as
little as 10 seconds



Mucosal absorption from smokeless tobacco is slower but more
sustained



Swallowed nicotine is not absorbed and eliminated from the
body
Nicotine


Following absorbtion, the elimination half-life of
nicotine is about 2 hours, thus it can accumulate with
repeated exposures over the course of a day



A typical smoker takes ~10 puffs of a cigarette over
about 5 minutes



Each cigarette delivers about 1 mg of nicotine



Thus, a person who smokes a pack a day (20
cigarettes) gets 200 hits of nicotine to the brain every
day, each one within 10 seconds after a puff
Physiologic and Behavioral
Effects of Nicotine


Increases heart rate



Increases cardiac output



Increases blood pressure



Suppresses appetite



Produces strong sense of pleasure and well-being



Improves task performance



Reduces anxiety
Nicotine Withdrawal


The effects of nicotine gradually diminish over a period of 30
minutes to 2 hours, and result in withdrawal effects


Dysphoria (disagreeable feeling) or depression



Insomnia



Irritability, frustration, anger



Anxiety



Difficulty concentrating



Restlessness



Decreased heart rate



Increased appetite
Effects of smoking and it’s quantity

1. Tobaco poisons are so powerful in miniscule quantities that
even smoking merely one cigarette can be enough to start the
fatal addictive process

2. See the article, "Lower Tar Makes No Difference," for an
example of why this is so.
3.

British Medical Journal, Vol 328, Issue # 7431 (10 January 2004)
Scope of the Problem in the
USA


21% of US citizens use tobacco products (mostly cigarettes)



440,000 deaths each year attributable to tobacco use; #1 cause of
death and disease


Heart Disease



Cancer



Stroke



Chronic Respiratory Disease



4,000 children and teens become regular users of tobacco each day



Direct medical care costs estimated to be $50 billion annually; loss of
productivity costs $47 billion



70% of smokers have made at least 1 attempt to quit or want to quit;
48% try to quit each year
Diseases Associated With
Tobacco Use


Cardiovascular Disease: 2-4x risk (coronary heart disease, myocardial
infarction, peripheral vascular disease {10x risk}, stroke {2x risk})



Pulmonary Disease 10x risk (emphysema, chronic bronchitis, asthma,
lung cancer {12-22x risk})



Pregnancy (stillbirth, spontaneous abortion, ↓ fetal growth,
premature birth, LBW, oral clefts)



Cigarette smokers die 13-14 years earlier than non-smokers
Oral Effects of Tobacco Use


Gingival inflammation and recession



Periodontal disease



Implant failure



Dry socket



Smoker’s melanosis



Nicotine stomatitis



Leukoplakia



Erythroplakia



Verrucous carcinoma



Squamous cell carcinoma
Oral Effects of Tobacco Use


Tooth staining



Tooth abrasion (chewing tobacco)



Halitosis



Hairy tongue



Diminished taste and smell
Benefits of Quitting


20 Minutes After Quitting: Heart rate drops.



12 hours After Quitting: Carbon monoxide level in blood drops to normal.



2 Weeks to 3 Months After Quitting: Heart attack risk begins to drop.
Lung function begins to improve.



1 to 9 Months After Quitting: Coughing and shortness of breath decrease.



1 Year After Quitting: Risk of coronary heart disease is half that of a nonsmoker’s.



5 Years After Quitting: Stroke risk is reduced to that of a nonsmoker’s.



10 Years After Quitting: Lung cancer death rate is about half that of a nonsmoker’s. Risk of cancers of the mouth, throat, esophagus, bladder,
kidney, and pancreas decreases.



15 Years After Quitting: Risk of coronary heart disease is back to that of a
nonsmoker’s.
?What Can We as Dentists Do


“Gold Standard”; the 5 A’s


Ask



Advise



Assess



Assist



Arrange
ASK


Ask every patient about their
tobacco use:


Current use?



How long used?



Form of tobacco used?



Quantity used daily?



If former user, how long
quit?



Ask if they have considered
quitting or are interested in
quitting



Ask about previous attempts to
quit and reasons for failure
ADVISE


Urge the tobacco user to quit, but don’t badger or shame them



Relate their tobacco use with their oral condition (periodontal
disease, lesions, halitosis, taste complaints)



Emphasize the benefits of quitting



Tell your patient that you will help them if they want to quit
ASSESS


Asses readiness to quit




be professional, gently persistent, and supportive

Ask directly: “Are you interested in quitting?”


If so, move on to the assist phase



If not, drop the subject, but continue to provide
motivational intervention at every opportunity



Be alert for “teaching moments”
ASSIST/ARRANGE


Provide self-help materials


“You Can Quit Smoking”



“Benefits of Quitting”



Refer patient to a counseling source (telephone help line)



Coordinate a smoking cessation program for the patient




Provide NRPs or medications for the patient if desired

Refer patient to a smoking cessation program
Outcome of the 5 A’s


Not good!



Most dentists and physicians are unaware of the initiative



Reasons cited for not engaging in the activity:


Takes too much time



Lack of training



Lack of reimbursement



Lack of knowledge about available referral sources



Lack of patient education materials
Difficulty Quitting


The more cigarettes smoked, or the more smokeless tobacco
used, the harder it is to quit



The longer a person has used tobacco products, the harder it is
to quit



The more tobacco usage is incorporated into daily activities, the
harder it is to quit
Nicotine Replacement Products


Nicotine patch (Nicoderm; Nicotrol: OTC)



Nicotine gum (Nicorette; OTC)



Nicotine lozenge (Commit; OTC)



Nicotine inhaler (Nicotrol; Rx)



Nicotine nasal spray (Nicotrol NS; Rx)
Use of Nicotine Replacement Products


Smokers need to maintain a blood level of nicotine around 15-18
ng/ml in order to prevent withdrawal symptoms



A single cigarette increases blood level of nicotine to 35-40
ng/ml



After about 25-30 minutes, the blood level falls back to 15-18
ng/ml



NRPs aim to provide a steady blood level of around 17 ng/ml in
order to prevent withdrawal symptoms



The patient then progressively learns to accept smaller and
smaller blood nicotine levels and then ultimately zero
NRT: Nicotine Transdermal Patch
((Available OTC


Nicoderm CQ; Generic; 3 strengths (21mg, 14mg, 7mg)



Nicotrol; 1 strength (15mg)



Dosages:


Nicoderm CQ or generic
 1-21mg

patch/day for 6 weeks, then

 1-14mg

patch/day for 2 weeks, then

 1-7


mg patch/day for 2 weeks

Nicotrol
 1-15mg


patch/day for no more than 16 hours

per day for 8 weeks
NRT: Nicotine Polacrilex (Gum)
((Available OTC


Nicorette; 2 strengths (2mg and 4mg)



Chewed briefly, then “parked” for 30 minutes; good control;
clock regulated better than prn



Dosage:


use 4mg gum up to 24 pieces per day; 2 weeks at 12/day,
then 1 week at 10/day, then 1 week at 9/day, etc.
NRT: Nicotine Lozenge
((Available OTC


Commit; 2 strengths (2mg and 4mg)



Parked between cheek and gum; periodically moistened by
placing on tongue and wetting with saliva



Provides 25% higher blood levels than gum



Absorption results in blood level of 86% of dose, but swallowing
results in only 2% of dose



Dosage:


Use 12 - 4gm lozenges per day, 1 about every 80 minutes;
maximum 20 pieces/day
NRT: Nicotine Nasal Spray
*Prescription only


Nicotrol NS



Rapidly absorbed; produces good nicotine blood levels; good
control



Good choice for very dependent user



Dosage:


8-40 doses/day for 3-6 months



A dose is 1 puff/nostril (6ng/ml)
3

doses/hour for 2 weeks, then

2

doses/hour for 4 weeks, then

1

dose/hour for 4 weeks
NRT: Nicotine Inhaler
*Prescription only


Nicotrol inhaler (cartridges)



Similar to smoking; rapid absorption



Generally not able to achieve optimum blood nicotine levels; not
the best choice for very dependent users; very
ineffective; expensive




Dosage:


6-16 cartridges/day for up to 6 months
Non-NRT Pharmacotherapeutic Agents


FDA Approved for smoking cessation





Bupropion (Zyban)
Varenicline (Chantix)

Non-FDA approved


Nortriptyline (Pamelor)
 tricyclic



antidepressant

Clonidine (Catapres)
 α-2

adrenergic agonist; antihypertensive
Bupropion SR (Zyban)
*Prescription only


Zyban; an antidepressant (Wellbutrin) but in a sustained release
form



As effective as nicotine patches when used alone



1 year quit rate about 10-15%



May be additional benefit when used in combination with other
NRT



Dosage:


150mg tablets



Start 1-2 weeks before quit date



Take a 150mg tablet QD for 3 days, then BID thereafter;
continue for 7-12 weeks; may need to continue for up to 6
months
Varenicline (Chantix)
*Prescription only


Chantix; a unique medication that partially activates nicotine
receptors to reduce the severity of craving for cigarettes and
withdrawal symptoms



Doubles the likelihood of quitting over bupropion and
quadruples it over placebo



1 year quit rate with varenicline alone is 22%



Dosage:


0.5 and 1.0 mg tablets



Start 1 week prior to quit date



0.5 mg daily for 3 days, then 0.5 mg twice a day for 4 days,
then 1.0 mg twice daily for 12 weeks
oral cancer
oral cancer
oral cancer
oral cancer

More Related Content

What's hot (20)

Cancer of head & neck - basics
Cancer of head & neck - basicsCancer of head & neck - basics
Cancer of head & neck - basics
Dr. SHEETAL KAPSE
 
Panoramic radiography OPG
Panoramic radiography OPGPanoramic radiography OPG
Panoramic radiography OPG
Dr. Sanjana Ravindra
 
TNM Staging Of Oral Cancer
TNM Staging Of Oral CancerTNM Staging Of Oral Cancer
TNM Staging Of Oral Cancer
Vibhuti Kaul
 
Radiation protection and dosimetry in dental radiology
Radiation protection and dosimetry in dental radiologyRadiation protection and dosimetry in dental radiology
Radiation protection and dosimetry in dental radiology
Mammootty Ik
 
POTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDERPOTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDER
AnweshaBiswas13
 
Radiopaque Lesions
Radiopaque LesionsRadiopaque Lesions
Radiopaque Lesions
Maryam Arbab
 
Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018
Varshu Goel
 
EPIDEMIOLOGY OF ORAL CANCER
EPIDEMIOLOGY OF ORAL CANCEREPIDEMIOLOGY OF ORAL CANCER
EPIDEMIOLOGY OF ORAL CANCER
Vineetha K
 
Cbct
CbctCbct
Cbct
Neha Sinha
 
Kaban protocol tmj ankylosis treatment new 2009
Kaban protocol tmj ankylosis treatment new 2009Kaban protocol tmj ankylosis treatment new 2009
Kaban protocol tmj ankylosis treatment new 2009
Dr Pratiksha Malhotra
 
Head And Neck Cancer
Head And Neck CancerHead And Neck Cancer
Head And Neck Cancer
Robert J Miller MD
 
clinically N0 neck in oral cancer
clinically N0 neck in oral cancerclinically N0 neck in oral cancer
clinically N0 neck in oral cancer
khyber college of dentistry
 
mandibular landmarks of radiograph
mandibular landmarks of radiographmandibular landmarks of radiograph
mandibular landmarks of radiograph
Afsana Kader A
 
OSTEORADIONECROSIS.pptx
OSTEORADIONECROSIS.pptxOSTEORADIONECROSIS.pptx
OSTEORADIONECROSIS.pptx
Cancer surgery By Royapettah Oncology Group
 
Principles Of Radiographic Interpretation
Principles Of Radiographic InterpretationPrinciples Of Radiographic Interpretation
Principles Of Radiographic Interpretation
DrJamilAlossaimi
 
Effects of radiation on oral tissues
Effects of radiation on oral tissuesEffects of radiation on oral tissues
Effects of radiation on oral tissues
Adwiti Vidushi
 
Extraoral radiography
Extraoral radiographyExtraoral radiography
Extraoral radiography
Basawaraj Biradar
 
Osteoradionecrosis
OsteoradionecrosisOsteoradionecrosis
Osteoradionecrosis
Mohammad Naved
 
CBCT
CBCTCBCT
CBCT
Ruhi Kashmiri
 
unilocular and multilocular radiolucencies
unilocular and multilocular radiolucenciesunilocular and multilocular radiolucencies
unilocular and multilocular radiolucencies
Dr Sourav Malhotra
 
Cancer of head & neck - basics
Cancer of head & neck - basicsCancer of head & neck - basics
Cancer of head & neck - basics
Dr. SHEETAL KAPSE
 
TNM Staging Of Oral Cancer
TNM Staging Of Oral CancerTNM Staging Of Oral Cancer
TNM Staging Of Oral Cancer
Vibhuti Kaul
 
Radiation protection and dosimetry in dental radiology
Radiation protection and dosimetry in dental radiologyRadiation protection and dosimetry in dental radiology
Radiation protection and dosimetry in dental radiology
Mammootty Ik
 
POTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDERPOTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDER
AnweshaBiswas13
 
Radiopaque Lesions
Radiopaque LesionsRadiopaque Lesions
Radiopaque Lesions
Maryam Arbab
 
Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018Management of oral cavity cancer 23072018
Management of oral cavity cancer 23072018
Varshu Goel
 
EPIDEMIOLOGY OF ORAL CANCER
EPIDEMIOLOGY OF ORAL CANCEREPIDEMIOLOGY OF ORAL CANCER
EPIDEMIOLOGY OF ORAL CANCER
Vineetha K
 
Kaban protocol tmj ankylosis treatment new 2009
Kaban protocol tmj ankylosis treatment new 2009Kaban protocol tmj ankylosis treatment new 2009
Kaban protocol tmj ankylosis treatment new 2009
Dr Pratiksha Malhotra
 
mandibular landmarks of radiograph
mandibular landmarks of radiographmandibular landmarks of radiograph
mandibular landmarks of radiograph
Afsana Kader A
 
Principles Of Radiographic Interpretation
Principles Of Radiographic InterpretationPrinciples Of Radiographic Interpretation
Principles Of Radiographic Interpretation
DrJamilAlossaimi
 
Effects of radiation on oral tissues
Effects of radiation on oral tissuesEffects of radiation on oral tissues
Effects of radiation on oral tissues
Adwiti Vidushi
 
unilocular and multilocular radiolucencies
unilocular and multilocular radiolucenciesunilocular and multilocular radiolucencies
unilocular and multilocular radiolucencies
Dr Sourav Malhotra
 

Viewers also liked (15)

Dangers of cancer
Dangers of cancerDangers of cancer
Dangers of cancer
pooh259803
 
Maureen Walsh , CEO, DeCare Dental
Maureen Walsh , CEO, DeCare DentalMaureen Walsh , CEO, DeCare Dental
Maureen Walsh , CEO, DeCare Dental
Investnet
 
Preventive dental care new
Preventive dental care newPreventive dental care new
Preventive dental care new
Dr. Monika Agrawal
 
Oral Cancer Prevention
Oral Cancer PreventionOral Cancer Prevention
Oral Cancer Prevention
Hasanain Alani
 
Lecture 1 introduction to preventive dental health
Lecture 1 introduction to preventive dental healthLecture 1 introduction to preventive dental health
Lecture 1 introduction to preventive dental health
Weam Banjar
 
Enhanced preventive dental services
Enhanced preventive dental servicesEnhanced preventive dental services
Enhanced preventive dental services
saskohc
 
Oral cancer
Oral cancerOral cancer
Oral cancer
Jyotindra Singh
 
Nutrition in Cancer Prevention
Nutrition in Cancer PreventionNutrition in Cancer Prevention
Nutrition in Cancer Prevention
nutritionistrepublic
 
Recent advances in Caries prevention
Recent advances in Caries preventionRecent advances in Caries prevention
Recent advances in Caries prevention
Dr. Roshni Maurya
 
Preventive Dentistry
Preventive DentistryPreventive Dentistry
Preventive Dentistry
Anas Miqdad
 
Prevention of dental caries
Prevention of dental cariesPrevention of dental caries
Prevention of dental caries
rushda087
 
Oral cancers
Oral cancersOral cancers
Oral cancers
Grant Medical College, Mumbai
 
Oral cancer
Oral cancerOral cancer
Oral cancer
Soyebo Oluseye
 
concepts of prevention in dentistry
concepts of prevention in dentistryconcepts of prevention in dentistry
concepts of prevention in dentistry
228amna
 
Prevention of dental diseases
Prevention of dental diseasesPrevention of dental diseases
Prevention of dental diseases
IAU Dent
 
Dangers of cancer
Dangers of cancerDangers of cancer
Dangers of cancer
pooh259803
 
Maureen Walsh , CEO, DeCare Dental
Maureen Walsh , CEO, DeCare DentalMaureen Walsh , CEO, DeCare Dental
Maureen Walsh , CEO, DeCare Dental
Investnet
 
Oral Cancer Prevention
Oral Cancer PreventionOral Cancer Prevention
Oral Cancer Prevention
Hasanain Alani
 
Lecture 1 introduction to preventive dental health
Lecture 1 introduction to preventive dental healthLecture 1 introduction to preventive dental health
Lecture 1 introduction to preventive dental health
Weam Banjar
 
Enhanced preventive dental services
Enhanced preventive dental servicesEnhanced preventive dental services
Enhanced preventive dental services
saskohc
 
Recent advances in Caries prevention
Recent advances in Caries preventionRecent advances in Caries prevention
Recent advances in Caries prevention
Dr. Roshni Maurya
 
Preventive Dentistry
Preventive DentistryPreventive Dentistry
Preventive Dentistry
Anas Miqdad
 
Prevention of dental caries
Prevention of dental cariesPrevention of dental caries
Prevention of dental caries
rushda087
 
concepts of prevention in dentistry
concepts of prevention in dentistryconcepts of prevention in dentistry
concepts of prevention in dentistry
228amna
 
Prevention of dental diseases
Prevention of dental diseasesPrevention of dental diseases
Prevention of dental diseases
IAU Dent
 

Similar to oral cancer (20)

(Tobacco damages and cure)
(Tobacco damages and cure)(Tobacco damages and cure)
(Tobacco damages and cure)
Dr.Anwer Alnahdi
 
say no to tobacco
say no to tobaccosay no to tobacco
say no to tobacco
Kirti Garg
 
Tobacco and Oral Health
Tobacco and Oral HealthTobacco and Oral Health
Tobacco and Oral Health
Pafbpharmacy
 
Ch20 01
Ch20 01Ch20 01
Ch20 01
shannon1120
 
Harmful Health Effects of Tobacco consumption
Harmful Health Effects of Tobacco consumptionHarmful Health Effects of Tobacco consumption
Harmful Health Effects of Tobacco consumption
Naina Mohamed, PhD
 
Combatting Tobacco
Combatting Tobacco Combatting Tobacco
Combatting Tobacco
AhsanManzar2
 
Tobacco day
Tobacco dayTobacco day
Tobacco day
Ravi Malik
 
Ch20 01
Ch20 01Ch20 01
Ch20 01
shannon1120
 
Tobacco/Nicotine presentation
Tobacco/Nicotine presentation Tobacco/Nicotine presentation
Tobacco/Nicotine presentation
cmariorenzi
 
Effects of Tobacco on Health
Effects of Tobacco on HealthEffects of Tobacco on Health
Effects of Tobacco on Health
Sanjoy Saha
 
No Smoking Day 2017 | It’s Time to Quit
No Smoking Day 2017 | It’s Time to QuitNo Smoking Day 2017 | It’s Time to Quit
No Smoking Day 2017 | It’s Time to Quit
Indus Health Plus
 
Tobacco 101 powerpoint
Tobacco 101 powerpointTobacco 101 powerpoint
Tobacco 101 powerpoint
vincedzieg
 
Tdt
TdtTdt
Tdt
bausher willayat
 
Tobacco Use
Tobacco UseTobacco Use
Tobacco Use
Samantha White
 
Smoking and its health risks
Smoking and its health risksSmoking and its health risks
Smoking and its health risks
Imibro2012
 
Smoking cessation
Smoking cessationSmoking cessation
Smoking cessation
michael_taylor
 
Smoking and its health risks
Smoking and its health risksSmoking and its health risks
Smoking and its health risks
Naina Mohamed, PhD
 
World No Tobacco Day 2010
World No Tobacco Day 2010World No Tobacco Day 2010
World No Tobacco Day 2010
Rahajeng Tunjungputri
 
Tobacco power point
Tobacco power pointTobacco power point
Tobacco power point
bradleyschrock
 
Tobacco
Tobacco Tobacco
Tobacco
bradley34
 
(Tobacco damages and cure)
(Tobacco damages and cure)(Tobacco damages and cure)
(Tobacco damages and cure)
Dr.Anwer Alnahdi
 
say no to tobacco
say no to tobaccosay no to tobacco
say no to tobacco
Kirti Garg
 
Tobacco and Oral Health
Tobacco and Oral HealthTobacco and Oral Health
Tobacco and Oral Health
Pafbpharmacy
 
Harmful Health Effects of Tobacco consumption
Harmful Health Effects of Tobacco consumptionHarmful Health Effects of Tobacco consumption
Harmful Health Effects of Tobacco consumption
Naina Mohamed, PhD
 
Combatting Tobacco
Combatting Tobacco Combatting Tobacco
Combatting Tobacco
AhsanManzar2
 
Tobacco/Nicotine presentation
Tobacco/Nicotine presentation Tobacco/Nicotine presentation
Tobacco/Nicotine presentation
cmariorenzi
 
Effects of Tobacco on Health
Effects of Tobacco on HealthEffects of Tobacco on Health
Effects of Tobacco on Health
Sanjoy Saha
 
No Smoking Day 2017 | It’s Time to Quit
No Smoking Day 2017 | It’s Time to QuitNo Smoking Day 2017 | It’s Time to Quit
No Smoking Day 2017 | It’s Time to Quit
Indus Health Plus
 
Tobacco 101 powerpoint
Tobacco 101 powerpointTobacco 101 powerpoint
Tobacco 101 powerpoint
vincedzieg
 
Smoking and its health risks
Smoking and its health risksSmoking and its health risks
Smoking and its health risks
Imibro2012
 

More from IAU Dent (20)

Odontogenic Infection
Odontogenic InfectionOdontogenic Infection
Odontogenic Infection
IAU Dent
 
Odontogenic Tumors
Odontogenic TumorsOdontogenic Tumors
Odontogenic Tumors
IAU Dent
 
Maxillofacial injuries
Maxillofacial injuriesMaxillofacial injuries
Maxillofacial injuries
IAU Dent
 
Impacted teeth
Impacted teethImpacted teeth
Impacted teeth
IAU Dent
 
Odontogenic Cysts
Odontogenic CystsOdontogenic Cysts
Odontogenic Cysts
IAU Dent
 
Chronic gingivitis
Chronic gingivitisChronic gingivitis
Chronic gingivitis
IAU Dent
 
Plaque control
Plaque controlPlaque control
Plaque control
IAU Dent
 
8. hypotension & hypertension
8. hypotension & hypertension8. hypotension & hypertension
8. hypotension & hypertension
IAU Dent
 
8. Prescription Writing
8. Prescription Writing8. Prescription Writing
8. Prescription Writing
IAU Dent
 
7. Adrenocorticosteriods
7. Adrenocorticosteriods7. Adrenocorticosteriods
7. Adrenocorticosteriods
IAU Dent
 
7.a. histamine & antihistaminics
7.a. histamine & antihistaminics7.a. histamine & antihistaminics
7.a. histamine & antihistaminics
IAU Dent
 
8 anticancer drugs
8  anticancer drugs8  anticancer drugs
8 anticancer drugs
IAU Dent
 
7 antibiotic-dental
7 antibiotic-dental7 antibiotic-dental
7 antibiotic-dental
IAU Dent
 
7.b. sedative hypnotics
7.b. sedative hypnotics 7.b. sedative hypnotics
7.b. sedative hypnotics
IAU Dent
 
6. peptic ulcer drugs 323
6. peptic ulcer drugs 3236. peptic ulcer drugs 323
6. peptic ulcer drugs 323
IAU Dent
 
6. anti drenergic
6. anti drenergic 6. anti drenergic
6. anti drenergic
IAU Dent
 
6 beta lactum drugs dental
6  beta lactum drugs dental6  beta lactum drugs dental
6 beta lactum drugs dental
IAU Dent
 
4.anti colinergic
4.anti colinergic 4.anti colinergic
4.anti colinergic
IAU Dent
 
5 aminoglycosides,macrolides, anti tb dental
5 aminoglycosides,macrolides, anti tb dental5 aminoglycosides,macrolides, anti tb dental
5 aminoglycosides,macrolides, anti tb dental
IAU Dent
 
5. opioid analgesics
5. opioid analgesics5. opioid analgesics
5. opioid analgesics
IAU Dent
 
Odontogenic Infection
Odontogenic InfectionOdontogenic Infection
Odontogenic Infection
IAU Dent
 
Odontogenic Tumors
Odontogenic TumorsOdontogenic Tumors
Odontogenic Tumors
IAU Dent
 
Maxillofacial injuries
Maxillofacial injuriesMaxillofacial injuries
Maxillofacial injuries
IAU Dent
 
Impacted teeth
Impacted teethImpacted teeth
Impacted teeth
IAU Dent
 
Odontogenic Cysts
Odontogenic CystsOdontogenic Cysts
Odontogenic Cysts
IAU Dent
 
Chronic gingivitis
Chronic gingivitisChronic gingivitis
Chronic gingivitis
IAU Dent
 
Plaque control
Plaque controlPlaque control
Plaque control
IAU Dent
 
8. hypotension & hypertension
8. hypotension & hypertension8. hypotension & hypertension
8. hypotension & hypertension
IAU Dent
 
8. Prescription Writing
8. Prescription Writing8. Prescription Writing
8. Prescription Writing
IAU Dent
 
7. Adrenocorticosteriods
7. Adrenocorticosteriods7. Adrenocorticosteriods
7. Adrenocorticosteriods
IAU Dent
 
7.a. histamine & antihistaminics
7.a. histamine & antihistaminics7.a. histamine & antihistaminics
7.a. histamine & antihistaminics
IAU Dent
 
8 anticancer drugs
8  anticancer drugs8  anticancer drugs
8 anticancer drugs
IAU Dent
 
7 antibiotic-dental
7 antibiotic-dental7 antibiotic-dental
7 antibiotic-dental
IAU Dent
 
7.b. sedative hypnotics
7.b. sedative hypnotics 7.b. sedative hypnotics
7.b. sedative hypnotics
IAU Dent
 
6. peptic ulcer drugs 323
6. peptic ulcer drugs 3236. peptic ulcer drugs 323
6. peptic ulcer drugs 323
IAU Dent
 
6. anti drenergic
6. anti drenergic 6. anti drenergic
6. anti drenergic
IAU Dent
 
6 beta lactum drugs dental
6  beta lactum drugs dental6  beta lactum drugs dental
6 beta lactum drugs dental
IAU Dent
 
4.anti colinergic
4.anti colinergic 4.anti colinergic
4.anti colinergic
IAU Dent
 
5 aminoglycosides,macrolides, anti tb dental
5 aminoglycosides,macrolides, anti tb dental5 aminoglycosides,macrolides, anti tb dental
5 aminoglycosides,macrolides, anti tb dental
IAU Dent
 
5. opioid analgesics
5. opioid analgesics5. opioid analgesics
5. opioid analgesics
IAU Dent
 

Recently uploaded (20)

Partial Reprogramming (OSK) Research Summary
Partial Reprogramming (OSK) Research SummaryPartial Reprogramming (OSK) Research Summary
Partial Reprogramming (OSK) Research Summary
maximuspeto
 
History collection of a patient with renal disorder.pptx
History collection of a patient with renal disorder.pptxHistory collection of a patient with renal disorder.pptx
History collection of a patient with renal disorder.pptx
Rishika Rawat
 
Anti malarial agents of pharmacology by Darade K.K
Anti malarial agents of pharmacology by Darade K.KAnti malarial agents of pharmacology by Darade K.K
Anti malarial agents of pharmacology by Darade K.K
krushna darade
 
Post-exercise thermoregulation and associated factors
Post-exercise thermoregulation and associated factorsPost-exercise thermoregulation and associated factors
Post-exercise thermoregulation and associated factors
Prof. Walid Kamal
 
NEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its uses
NEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its usesNEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its uses
NEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its uses
srirambonu
 
clinical case presentation of aesthetically compromised patient with reduce...
clinical case  presentation of aesthetically  compromised patient with reduce...clinical case  presentation of aesthetically  compromised patient with reduce...
clinical case presentation of aesthetically compromised patient with reduce...
Rajesh Karmaker
 
PHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptx
PHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptxPHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptx
PHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptx
Gadzika Gunda
 
L1-2..INTRODUCTION to ENDOCRINOLOGY.pptx
L1-2..INTRODUCTION to ENDOCRINOLOGY.pptxL1-2..INTRODUCTION to ENDOCRINOLOGY.pptx
L1-2..INTRODUCTION to ENDOCRINOLOGY.pptx
Dr Bilal Natiq
 
MIDFACIAL_DEGLOVING-SarayuShivani_U.pptx
MIDFACIAL_DEGLOVING-SarayuShivani_U.pptxMIDFACIAL_DEGLOVING-SarayuShivani_U.pptx
MIDFACIAL_DEGLOVING-SarayuShivani_U.pptx
Sarayu Shivani Udhayakumar
 
Designing for Menopause: How to Design with Empathy for People in Transition
Designing for Menopause: How to Design with Empathy for People in TransitionDesigning for Menopause: How to Design with Empathy for People in Transition
Designing for Menopause: How to Design with Empathy for People in Transition
1508 A/S
 
BIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptx
BIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptxBIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptx
BIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptx
drnidhimnd
 
What is PharmD.pptx Its about pharm.d course
What is PharmD.pptx Its about pharm.d courseWhat is PharmD.pptx Its about pharm.d course
What is PharmD.pptx Its about pharm.d course
surisettirajesh7
 
A BRIEF STUDY OF REGIONAL REPERTORY (3).pdf
A BRIEF STUDY OF REGIONAL REPERTORY (3).pdfA BRIEF STUDY OF REGIONAL REPERTORY (3).pdf
A BRIEF STUDY OF REGIONAL REPERTORY (3).pdf
sadanandarya1
 
recent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptx
recent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptxrecent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptx
recent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptx
Dr Shraddha Mishra
 
Hepatorenal Syndrome.pptx hepatorenal syndrome
Hepatorenal Syndrome.pptx hepatorenal syndromeHepatorenal Syndrome.pptx hepatorenal syndrome
Hepatorenal Syndrome.pptx hepatorenal syndrome
wxtbzvjypr
 
APRIL 2025 Oncology Cartoons by Dr Kanhu Charan Patro
APRIL 2025 Oncology Cartoons by Dr Kanhu Charan PatroAPRIL 2025 Oncology Cartoons by Dr Kanhu Charan Patro
APRIL 2025 Oncology Cartoons by Dr Kanhu Charan Patro
Kanhu Charan
 
Mission Nutrition RETREAT Spring 2024.pptx
Mission Nutrition RETREAT Spring 2024.pptxMission Nutrition RETREAT Spring 2024.pptx
Mission Nutrition RETREAT Spring 2024.pptx
JessShirley3
 
Rasayan Therapy as per NCISM syllabus 25
Rasayan Therapy as per NCISM syllabus 25Rasayan Therapy as per NCISM syllabus 25
Rasayan Therapy as per NCISM syllabus 25
DrSakshi Bhardwaj
 
PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...
PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...
PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...
Kanhu Charan
 
EMERGING AND REEMERGING INFECTIOUS DISEASES.pptx
EMERGING AND REEMERGING INFECTIOUS DISEASES.pptxEMERGING AND REEMERGING INFECTIOUS DISEASES.pptx
EMERGING AND REEMERGING INFECTIOUS DISEASES.pptx
AnuragVerma491530
 
Partial Reprogramming (OSK) Research Summary
Partial Reprogramming (OSK) Research SummaryPartial Reprogramming (OSK) Research Summary
Partial Reprogramming (OSK) Research Summary
maximuspeto
 
History collection of a patient with renal disorder.pptx
History collection of a patient with renal disorder.pptxHistory collection of a patient with renal disorder.pptx
History collection of a patient with renal disorder.pptx
Rishika Rawat
 
Anti malarial agents of pharmacology by Darade K.K
Anti malarial agents of pharmacology by Darade K.KAnti malarial agents of pharmacology by Darade K.K
Anti malarial agents of pharmacology by Darade K.K
krushna darade
 
Post-exercise thermoregulation and associated factors
Post-exercise thermoregulation and associated factorsPost-exercise thermoregulation and associated factors
Post-exercise thermoregulation and associated factors
Prof. Walid Kamal
 
NEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its uses
NEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its usesNEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its uses
NEONATAL HYPOGLYCEMIA, oral 40% dextrose gel and its uses
srirambonu
 
clinical case presentation of aesthetically compromised patient with reduce...
clinical case  presentation of aesthetically  compromised patient with reduce...clinical case  presentation of aesthetically  compromised patient with reduce...
clinical case presentation of aesthetically compromised patient with reduce...
Rajesh Karmaker
 
PHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptx
PHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptxPHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptx
PHARMACOLOGY UNIT 2 LEGAL, ETHICAL AND CULTURAL ASPECTS OF PHARMACOLOGY-1.pptx
Gadzika Gunda
 
L1-2..INTRODUCTION to ENDOCRINOLOGY.pptx
L1-2..INTRODUCTION to ENDOCRINOLOGY.pptxL1-2..INTRODUCTION to ENDOCRINOLOGY.pptx
L1-2..INTRODUCTION to ENDOCRINOLOGY.pptx
Dr Bilal Natiq
 
Designing for Menopause: How to Design with Empathy for People in Transition
Designing for Menopause: How to Design with Empathy for People in TransitionDesigning for Menopause: How to Design with Empathy for People in Transition
Designing for Menopause: How to Design with Empathy for People in Transition
1508 A/S
 
BIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptx
BIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptxBIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptx
BIOMECHANICS OF THE MOVEMENTS AROUND ELBOW JOINT.pptx
drnidhimnd
 
What is PharmD.pptx Its about pharm.d course
What is PharmD.pptx Its about pharm.d courseWhat is PharmD.pptx Its about pharm.d course
What is PharmD.pptx Its about pharm.d course
surisettirajesh7
 
A BRIEF STUDY OF REGIONAL REPERTORY (3).pdf
A BRIEF STUDY OF REGIONAL REPERTORY (3).pdfA BRIEF STUDY OF REGIONAL REPERTORY (3).pdf
A BRIEF STUDY OF REGIONAL REPERTORY (3).pdf
sadanandarya1
 
recent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptx
recent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptxrecent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptx
recent HIV/AIDS drugs and pharmacology by Dr Shraddha.pptx
Dr Shraddha Mishra
 
Hepatorenal Syndrome.pptx hepatorenal syndrome
Hepatorenal Syndrome.pptx hepatorenal syndromeHepatorenal Syndrome.pptx hepatorenal syndrome
Hepatorenal Syndrome.pptx hepatorenal syndrome
wxtbzvjypr
 
APRIL 2025 Oncology Cartoons by Dr Kanhu Charan Patro
APRIL 2025 Oncology Cartoons by Dr Kanhu Charan PatroAPRIL 2025 Oncology Cartoons by Dr Kanhu Charan Patro
APRIL 2025 Oncology Cartoons by Dr Kanhu Charan Patro
Kanhu Charan
 
Mission Nutrition RETREAT Spring 2024.pptx
Mission Nutrition RETREAT Spring 2024.pptxMission Nutrition RETREAT Spring 2024.pptx
Mission Nutrition RETREAT Spring 2024.pptx
JessShirley3
 
Rasayan Therapy as per NCISM syllabus 25
Rasayan Therapy as per NCISM syllabus 25Rasayan Therapy as per NCISM syllabus 25
Rasayan Therapy as per NCISM syllabus 25
DrSakshi Bhardwaj
 
PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...
PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...
PROCEDURE OF INTERSTITIAL BRACHYTHERAPY FOR SKIN AND BUCCAL MUCOSA UNDER LOCA...
Kanhu Charan
 
EMERGING AND REEMERGING INFECTIOUS DISEASES.pptx
EMERGING AND REEMERGING INFECTIOUS DISEASES.pptxEMERGING AND REEMERGING INFECTIOUS DISEASES.pptx
EMERGING AND REEMERGING INFECTIOUS DISEASES.pptx
AnuragVerma491530
 

oral cancer

  • 1. Prevention Strategies for Oral Cancer Aiman A. Ali, DDS, PhD. Associate professor Oral Pathology and Medicine
  • 2. How to prevent the occurrence of a disease? A disease with simple etiology  Causal factor  Dental caries Traumatic exposure Chemical irritations Thermal irritations Fracture of the crown Disease Pulpitis Multifactorial disease (dental caries or oral cancer)?
  • 3. How to prevent the occurrence of a disease? Etiology of oral cancer  Smoking If we want to prevent  Chronic irritations the occurrence of  Chronic diseases oral cancer we have  Alcohol to control all these factors !!!  Hereditary Is it possible?  Genetic aberrations  Others such as viruses, diet…etc.
  • 4. General statistics  Thirty percent of all cancer deaths are caused by tobacco.  Over 80% of lung cancer deaths are caused by tobacco.  The lung cancer death rate for men was 4.9 per 100,000 in 1930 and it has increased to 75.6 per 100,000 in the decade of 1990.  Ninety-two percent of oral squamous cell carcinoma are attributable to tobacco usage.
  • 5. Statistics and incidence The incidence of lung cancer is highly correlated with smoking.
  • 7. The tobacco plant was first brought to Europe in 1558 by the Spanish physician Francisco Fernandes Aiman A. Ali, DDS, PhD. 2008
  • 8. Tobacco and related oral habits  Smoking      Cigarette (normal, black, light, natural….) Pipe Water-pipe Reverse smoking Cigar  Smokeless    Passive Snuff, Tombak and similar products Chewing the tobacco leaves smoking Aiman A. Ali, DDS, PhD. 2009
  • 9. Tobacco and related oral habits  Smoking  Cigarette (normal, black, light, natural….)
  • 10. Tobacco and related oral habits  Smoking  Pipe
  • 11. Tobacco and related oral habits  Smoking  Water-pipe
  • 12. Tobacco and related oral habits  Smoking  Reverse smoking
  • 13. Tobacco and related oral habits  Smoking  Cigar
  • 14. Tobacco and related oral habits  Smokeless  Snuff, Tombak and similar products
  • 15. Tobacco and related oral habits  Smokeless  Chewing the tobacco leaves
  • 16. Tobacco and related oral habits  Passive smoking
  • 17. Smoking any tobacco product, *%, Males * WHO Report on the Global Tobacco Epidemic, 2008
  • 18. Smoking any tobacco product, %, Females * WHO Report on the Global Tobacco Epidemic, 2008
  • 19. Constituents  "Chemical analysis shows the tobacco leaf/smoke to contain an unusual number of constituents. Nicotine, Nitric, phosphoric, pictic, nicotianine, hydrochloric, citric, acetic, ulmic acids tobacco acid or malic acid sulphuric, oxalic, Acetaldehyde, acrolein, ammonia, carbon monoxide, formaldehyde, hydrogen cyanide, hydrogen sulfide, methyl chloride, nitrogen dioxide And others: Benzopyrene, Tar, Naphthalene, arsenic and others Hinds JID, The Use of Tobacco (Nashville, Tenn: Cumberland Presbyterian Publishing House, 1882), p 36 Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service, PHS Pub 1103, Chapter 6, Table 4, p 60 (1964)
  • 20. Constituents Chemical structure of the carcinogen benzopyrene diol epoxide Benzopyrene, a major mutagen in tobacco smoke, in an adduct to DNA* * PDB 1JDG
  • 21. Constituents  "Moreover, there is no question that arsenic . . . is definitely an active carcinogen on human tissue. . . .  the arsenic content of American cigarettes has increased from two to six times in a period of 25 years.  One popular American brand contains from 41 to 52.5 micrograms of arsenic, of which one third remains in the butt, one third is in the ash, and one third goes into the smoke.  About five micrograms of arsenic trioxide is inhaled from each cigarette. Alton Ochsner, Smoking and Your Life (New York: Julian Messner Pub, 1954 rev 1964), p 15. A large sample of native arsenic. Aiman A. Ali, DDS, PhD. 2008
  • 22. Constituents  Cigarettes and other forms of tobacco are extremely addicting and nicotine is the drug that causes that addiction  Pharmacologic and behavioral characteristics of nicotine addiction are similar to those of heroin, cocaine, and methamphetamine Nicotine molecule
  • 23. Nicotine  Absorbed by the lungs via inhalational route  Absorbed topically through skin and mucous lining of the mouth  Rapidly distributed after inhalation and reaches the brain in as little as 10 seconds  Mucosal absorption from smokeless tobacco is slower but more sustained  Swallowed nicotine is not absorbed and eliminated from the body
  • 24. Nicotine  Following absorbtion, the elimination half-life of nicotine is about 2 hours, thus it can accumulate with repeated exposures over the course of a day  A typical smoker takes ~10 puffs of a cigarette over about 5 minutes  Each cigarette delivers about 1 mg of nicotine  Thus, a person who smokes a pack a day (20 cigarettes) gets 200 hits of nicotine to the brain every day, each one within 10 seconds after a puff
  • 25. Physiologic and Behavioral Effects of Nicotine  Increases heart rate  Increases cardiac output  Increases blood pressure  Suppresses appetite  Produces strong sense of pleasure and well-being  Improves task performance  Reduces anxiety
  • 26. Nicotine Withdrawal  The effects of nicotine gradually diminish over a period of 30 minutes to 2 hours, and result in withdrawal effects  Dysphoria (disagreeable feeling) or depression  Insomnia  Irritability, frustration, anger  Anxiety  Difficulty concentrating  Restlessness  Decreased heart rate  Increased appetite
  • 27. Effects of smoking and it’s quantity 1. Tobaco poisons are so powerful in miniscule quantities that even smoking merely one cigarette can be enough to start the fatal addictive process 2. See the article, "Lower Tar Makes No Difference," for an example of why this is so. 3. British Medical Journal, Vol 328, Issue # 7431 (10 January 2004)
  • 28. Scope of the Problem in the USA  21% of US citizens use tobacco products (mostly cigarettes)  440,000 deaths each year attributable to tobacco use; #1 cause of death and disease  Heart Disease  Cancer  Stroke  Chronic Respiratory Disease  4,000 children and teens become regular users of tobacco each day  Direct medical care costs estimated to be $50 billion annually; loss of productivity costs $47 billion  70% of smokers have made at least 1 attempt to quit or want to quit; 48% try to quit each year
  • 29. Diseases Associated With Tobacco Use  Cardiovascular Disease: 2-4x risk (coronary heart disease, myocardial infarction, peripheral vascular disease {10x risk}, stroke {2x risk})  Pulmonary Disease 10x risk (emphysema, chronic bronchitis, asthma, lung cancer {12-22x risk})  Pregnancy (stillbirth, spontaneous abortion, ↓ fetal growth, premature birth, LBW, oral clefts)  Cigarette smokers die 13-14 years earlier than non-smokers
  • 30. Oral Effects of Tobacco Use  Gingival inflammation and recession  Periodontal disease  Implant failure  Dry socket  Smoker’s melanosis  Nicotine stomatitis  Leukoplakia  Erythroplakia  Verrucous carcinoma  Squamous cell carcinoma
  • 31. Oral Effects of Tobacco Use
  • 32.  Tooth staining  Tooth abrasion (chewing tobacco)  Halitosis  Hairy tongue  Diminished taste and smell
  • 33. Benefits of Quitting  20 Minutes After Quitting: Heart rate drops.  12 hours After Quitting: Carbon monoxide level in blood drops to normal.  2 Weeks to 3 Months After Quitting: Heart attack risk begins to drop. Lung function begins to improve.  1 to 9 Months After Quitting: Coughing and shortness of breath decrease.  1 Year After Quitting: Risk of coronary heart disease is half that of a nonsmoker’s.  5 Years After Quitting: Stroke risk is reduced to that of a nonsmoker’s.  10 Years After Quitting: Lung cancer death rate is about half that of a nonsmoker’s. Risk of cancers of the mouth, throat, esophagus, bladder, kidney, and pancreas decreases.  15 Years After Quitting: Risk of coronary heart disease is back to that of a nonsmoker’s.
  • 34. ?What Can We as Dentists Do  “Gold Standard”; the 5 A’s  Ask  Advise  Assess  Assist  Arrange
  • 35. ASK  Ask every patient about their tobacco use:  Current use?  How long used?  Form of tobacco used?  Quantity used daily?  If former user, how long quit?  Ask if they have considered quitting or are interested in quitting  Ask about previous attempts to quit and reasons for failure
  • 36. ADVISE  Urge the tobacco user to quit, but don’t badger or shame them  Relate their tobacco use with their oral condition (periodontal disease, lesions, halitosis, taste complaints)  Emphasize the benefits of quitting  Tell your patient that you will help them if they want to quit
  • 37. ASSESS  Asses readiness to quit   be professional, gently persistent, and supportive Ask directly: “Are you interested in quitting?”  If so, move on to the assist phase  If not, drop the subject, but continue to provide motivational intervention at every opportunity  Be alert for “teaching moments”
  • 38. ASSIST/ARRANGE  Provide self-help materials  “You Can Quit Smoking”  “Benefits of Quitting”  Refer patient to a counseling source (telephone help line)  Coordinate a smoking cessation program for the patient   Provide NRPs or medications for the patient if desired Refer patient to a smoking cessation program
  • 39. Outcome of the 5 A’s  Not good!  Most dentists and physicians are unaware of the initiative  Reasons cited for not engaging in the activity:  Takes too much time  Lack of training  Lack of reimbursement  Lack of knowledge about available referral sources  Lack of patient education materials
  • 40. Difficulty Quitting  The more cigarettes smoked, or the more smokeless tobacco used, the harder it is to quit  The longer a person has used tobacco products, the harder it is to quit  The more tobacco usage is incorporated into daily activities, the harder it is to quit
  • 41. Nicotine Replacement Products  Nicotine patch (Nicoderm; Nicotrol: OTC)  Nicotine gum (Nicorette; OTC)  Nicotine lozenge (Commit; OTC)  Nicotine inhaler (Nicotrol; Rx)  Nicotine nasal spray (Nicotrol NS; Rx)
  • 42. Use of Nicotine Replacement Products  Smokers need to maintain a blood level of nicotine around 15-18 ng/ml in order to prevent withdrawal symptoms  A single cigarette increases blood level of nicotine to 35-40 ng/ml  After about 25-30 minutes, the blood level falls back to 15-18 ng/ml  NRPs aim to provide a steady blood level of around 17 ng/ml in order to prevent withdrawal symptoms  The patient then progressively learns to accept smaller and smaller blood nicotine levels and then ultimately zero
  • 43. NRT: Nicotine Transdermal Patch ((Available OTC  Nicoderm CQ; Generic; 3 strengths (21mg, 14mg, 7mg)  Nicotrol; 1 strength (15mg)  Dosages:  Nicoderm CQ or generic  1-21mg patch/day for 6 weeks, then  1-14mg patch/day for 2 weeks, then  1-7  mg patch/day for 2 weeks Nicotrol  1-15mg  patch/day for no more than 16 hours per day for 8 weeks
  • 44. NRT: Nicotine Polacrilex (Gum) ((Available OTC  Nicorette; 2 strengths (2mg and 4mg)  Chewed briefly, then “parked” for 30 minutes; good control; clock regulated better than prn  Dosage:  use 4mg gum up to 24 pieces per day; 2 weeks at 12/day, then 1 week at 10/day, then 1 week at 9/day, etc.
  • 45. NRT: Nicotine Lozenge ((Available OTC  Commit; 2 strengths (2mg and 4mg)  Parked between cheek and gum; periodically moistened by placing on tongue and wetting with saliva  Provides 25% higher blood levels than gum  Absorption results in blood level of 86% of dose, but swallowing results in only 2% of dose  Dosage:  Use 12 - 4gm lozenges per day, 1 about every 80 minutes; maximum 20 pieces/day
  • 46. NRT: Nicotine Nasal Spray *Prescription only  Nicotrol NS  Rapidly absorbed; produces good nicotine blood levels; good control  Good choice for very dependent user  Dosage:  8-40 doses/day for 3-6 months  A dose is 1 puff/nostril (6ng/ml) 3 doses/hour for 2 weeks, then 2 doses/hour for 4 weeks, then 1 dose/hour for 4 weeks
  • 47. NRT: Nicotine Inhaler *Prescription only  Nicotrol inhaler (cartridges)  Similar to smoking; rapid absorption  Generally not able to achieve optimum blood nicotine levels; not the best choice for very dependent users; very ineffective; expensive   Dosage:  6-16 cartridges/day for up to 6 months
  • 48. Non-NRT Pharmacotherapeutic Agents  FDA Approved for smoking cessation    Bupropion (Zyban) Varenicline (Chantix) Non-FDA approved  Nortriptyline (Pamelor)  tricyclic  antidepressant Clonidine (Catapres)  α-2 adrenergic agonist; antihypertensive
  • 49. Bupropion SR (Zyban) *Prescription only  Zyban; an antidepressant (Wellbutrin) but in a sustained release form  As effective as nicotine patches when used alone  1 year quit rate about 10-15%  May be additional benefit when used in combination with other NRT  Dosage:  150mg tablets  Start 1-2 weeks before quit date  Take a 150mg tablet QD for 3 days, then BID thereafter; continue for 7-12 weeks; may need to continue for up to 6 months
  • 50. Varenicline (Chantix) *Prescription only  Chantix; a unique medication that partially activates nicotine receptors to reduce the severity of craving for cigarettes and withdrawal symptoms  Doubles the likelihood of quitting over bupropion and quadruples it over placebo  1 year quit rate with varenicline alone is 22%  Dosage:  0.5 and 1.0 mg tablets  Start 1 week prior to quit date  0.5 mg daily for 3 days, then 0.5 mg twice a day for 4 days, then 1.0 mg twice daily for 12 weeks